Background: Diabetic nephropathy (DN) is one of the most important microvascular complications of diabetes mellitus. However, the underlying mechanisms remain unclear. We studied the expression characteristics of angiopoietin-like 2 (ANGPTL2), a novel DN-associated growth factor identified in our previous gene chip screening. Methods: Glomeruli were microdissected from renal biopsies from 24 patients with DN and 8 donor controls. The expression of ANGPTL2 was assessed by RT-PCR and immunohistochemistry, and then correlated with clinical and pathological indices of glomerular injury. Results: Consistent with the results of the gene chip experiment, abundant expression of ANGPTL2 was found more frequently in diabetic glomeruli as compared to donor controls (95 vs. 38%, χ2 = 15.9, p < 0.01). ANGPTL2 mRNA upregulation was more prominent in glomeruli with less microaneurysm (22 vs. 66%, p < 0.05), inflammatory influx (6 vs. 50%, p < 0.05) or endothelial foam cell formation (11 vs. 53%, p < 0.05). Immunostaining revealed an upregulation of ANGPTL2 protein in hypertrophied diabetic glomeruli, mainly distributed in podocytes, which were supposed to be the origin of ANGPTL2. Conclusion: The upregulation of ANGPTL2 in diabetic glomerulopathy shows a close relationship to abnormal microvasculature and endothelial inflammation. ANGPTL2 may play an important role in the pathogenesis of diabetic glomerulopathy.

Journal Section:
Original Paper
Keywords:
ANGPTL2 expression, Diabetic nephropathy, Microvascular complications
1.
Gealekman O, Brodsky SV, Zhang F, et al: Endothelial dysfunction as a modifier of angiogenic response in Zucker diabetic fat rat: amelioration with ebselen. Kidney Int 2004;66:2337&ndash;2347.
[PubMed]
https://doi.org/10.1111%2Fj.1523-1755.2004.66035.x
2.
Raptis AE, Viberti G: Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes 2001;109(suppl 2):S424&ndash;S437.
https://doi.org/10.1055%2Fs-2001-18600</pub-id><pub-id pub-id-type="pmid">11460589
3.
Patan S: Vasculogenesis and angiogenesis as mechanisms of vascular network formation, growth and remodeling. J Neurooncol 2000;50:1&ndash;15.
[PubMed]
https://doi.org/10.1023%2FA%3A1006493130855
4.
Woolf AS, Yuan HT: Angiopoietin growth factors and Tie receptor tyrosine kinases in renal vascular development. Pediatr Nephrol 2001;16:177&ndash;184.
[PubMed]
https://doi.org/10.1007%2Fs004670000509
5.
Satchell SC, Anderson KL, Mathieson PW, et al: Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties. J Am Soc Nephrol 2004;15:566&ndash;574.
[PubMed]
https://doi.org/10.1097%2F01.ASN.0000115397.22519.03
6.
Satchell SC, Harper SJ, Tooke JE, et al: Human podocytes express angiopoietin 1, a potential regulator of glomerular vascular endothelial growth factor. J Am Soc Nephrol 2002;13:544&ndash;550.
[PubMed]
7.
Pizurki L, Zhou Z, Glynos K, et al: Angiopoietin-1 inhibits endothelial permeability, neutrophil adherence and IL-8 production. Br J Pharmacol 2003;139:329&ndash;336.
[PubMed]
https://doi.org/10.1038%2Fsj.bjp.0705259
8.
Satchell SC, Mathieson PW: Angiopoietins: microvascular modulators with potential roles in glomerular pathophysiology. J Nephrol 2003;16:168&ndash;178.
[PubMed]
9.
Kim I, Moon SO, Koh KN, et al: Molecular cloning, expression, and characterization of angiopoietin-related protein: angiopoietin-related protein induces endothelial cell sprouting. J Biol Chem 1999;274:26523&ndash;26528.
[PubMed]
https://doi.org/10.1074%2Fjbc.274.37.26523
10.
Wu YC, Liu ZH, Zeng CH, et al: Glomerular gene expression profiles in patients with diabetic nephropathy. Chin J Nephrol Dial Transplant 2004;13:503&ndash;511.
11.
Liu ZH, Hu KB, Zhou H, et al: Altered expression of vascular endothelial growth factor and its receptor in the kidneys of patients with type 2 diabetic nephropathy. Chin J Nephrol Dial Transplant 2001;10:401&ndash;406.
12.
Schrijvers BF, An S: From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 2004;25:971&ndash;1010.
[PubMed]
https://doi.org/10.1210%2Fer.2003-0018
13.
Singh AK, Gudehithlu KP, Pegoraro AA: Vascular factors altered in glucose-treated mesangial cells and diabetic glomeruli: changes in vascular factors impair endothelial cell growth and matrix. Lab Invest 2004;84:597&ndash;606.
[PubMed]
https://doi.org/10.1038%2Flabinvest.3700082
14.
Dedov II, Shestakov MV, Kochemasova TV, et al: Endothelial dysfunction in the development of vascular complications in diabetes mellitus. Ross Fiziol Zh Im I M Sechenova 2001;87:1073&ndash;1084.
[PubMed]
15.
Cha DR, Kang YS, Han SY, et al: Vascular endothelial growth factor is increased during early stage of diabetic nephropathy in type II diabetic rats. J Endocrinol 2004;183:183&ndash;194.
[PubMed]
https://doi.org/10.1677%2Fjoe.1.05647
16.
Lorenzi M, Cagliero E: Pathobiology of endothelial and other vascular cells in diabetes mellitus: Call for data. Diabetes 1991;40:653&ndash;659.
[PubMed]
https://doi.org/10.2337%2Fdiabetes.40.6.653
17.
Yamamoto Y, Maeshima Y, Kitayama H, et al: Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes 2004;53:1831&ndash;1840.
[PubMed]
https://doi.org/10.2337%2Fdiabetes.53.7.1831
18.
Joussen AM, Poulaki V, Tsujikawa A, et al: Suppression of diabetic retinopathy with angiopoietin 1. Am J Pathol 2002;160:1683&ndash;1693.
[PubMed]
19.
Pizurki L, Zhou Z, Glynos K, et al: Angiopoietin-1 inhibits endothelial permeability, neutrophil adherence and IL-8 production. Br J Pharmacol 2003;139:329&ndash;336.
[PubMed]
https://doi.org/10.1038%2Fsj.bjp.0705259
© 2007 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2007
You do not currently have access to this content.